FIU Discovery

Abstract 361: MicroRNA expression in murine spontaneous non-small cell lung cancer and human cell lines post-treatment of PRIMA-1.  CANCER RESEARCH.  82:361-361.

Abstract 6184: Kras Co-mutations lead to resistance to mutant TP53 targeted therapy in mouse models of spontaneous non-small cell lung cancer.  CANCER RESEARCH.  82:6184-6184.

Pembrolizumab activity in patients with Fanconi anemia repair pathway competent and deficient tumors

A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.  CANCER CHEMOTHERAPY AND PHARMACOLOGY.  89:721-735.

Ammonia stimulates SCAP/Insig dissociation and SREBP-1 activation to promote lipogenesis and tumour growth

Deregulation of AKT-mTOR Signaling Contributes to Chemoradiation Resistance in Lung Squamous Cell Carcinoma.  MOLECULAR CANCER RESEARCH.  20:425-433.

Abstract 1351: Targeting mutant p53 protein in spontaneous non-small cell lung cancers in transgenic mice.  CANCER RESEARCH.  81:1351-1351.

MiRNA-200C expression in Fanconi anemia pathway functionally deficient lung cancers.  SCIENTIFIC REPORTS.  11.

Computational identification of biomarker genes for lung cancer considering treatment and non-treatment studies.  BMC BIOINFORMATICS.  21.

The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study

Type of TP53 mutation influences oncogenic potential and spectrum of associated K-ras mutations in lung-specific transgenic mice.  INTERNATIONAL JOURNAL OF CANCER.  145:2418-2426.

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC

Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency..  JOURNAL OF CLINICAL ONCOLOGY.  36:tps3108-tps3108.

Oral Presentations

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852)

Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair.  JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.  108.

Rad51C-ATXN7 fusion gene expression in colorectal tumors

Clinical and pathological characterization of patients (pts) with functional deficiency of the fanconi anemia (FA) pathway..  JOURNAL OF CLINICAL ONCOLOGY.  34:e23247-e23247.

XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression

Overexpression of Rad51C splice variants in colorectal tumors

FANCD2 Is a Potential Therapeutic Target and Biomarker in Alveolar Rhabdomyosarcoma Harboring the PAX3-FOXO1 Fusion Gene.  CLINICAL CANCER RESEARCH.  20:3884-3895.

NRAS isoforms differentially affect downstream pathways, cell growth, and cell transformation.  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA.  111:4179-4184.

Fanconi anemia repair pathway dysfunction, a potential therapeutic target in lung cancer

Cellular localization of protein arginine methyltransferase-5 correlates with grade of lung tumors

Cellular Localization of Protein Arginine Methyltransferase-5 Correlates With Grade of Pulmonary Neuroendocrine Tumors.  AMERICAN JOURNAL OF CLINICAL PATHOLOGY.  140:a090-a090.

Assessment of FANCD2 nuclear foci formation in paraffin-embedded tumors: a potential patient-enrichment strategy for treatment with DNA interstrand crosslinking agents.  TRANSLATIONAL RESEARCH.  161:156-164.

Research Highlights.  PERSONALIZED MEDICINE.  9:329-332.

Germline Stem Cell Gene PIWIL2 Mediates DNA Repair through Relaxation of Chromatin.  PLOS ONE.  6.

MDM2 (transformed mouse 3T3 cell double minute 2, p53 binding protein)

RCHY1 (ring finger and CHY zinc finger domain containing 1)

The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods

MicroRNA-34a is an important component of PRIMA-1-induced apoptotic network in human lung cancer cells.  INTERNATIONAL JOURNAL OF CANCER.  127:313-320.

Targeting fanconi anemia (FA) repair pathway deficiency for treatment with PARP inhibitors..  JOURNAL OF CLINICAL ONCOLOGY.  28:tps168-tps168.

Expression of a Mutant p53 Results in an Age-Related Demographic Shift in Spontaneous Lung Tumor Formation in Transgenic Mice.  PLOS ONE.  4.

Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.  CANCER CHEMOTHERAPY AND PHARMACOLOGY.  63:1073-1082.

OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis.  INTERNATIONAL JOURNAL OF CANCER.  123:2923-2930.

Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice

Effect of dichloroacetate in combination with chemotherapy on human lung cancer cells.  JOURNAL OF CLINICAL ONCOLOGY.  26:14637-14637.

Precancerous Stem Cells Have the Potential for both Benign and Malignant Differentiation.  PLOS ONE.  2.

Thalidomide and celecoxib as potential modulators of irinotecan's activity in cancer patients.  CANCER CHEMOTHERAPY AND PHARMACOLOGY.  59:23-33.

Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.  EXPERIMENTAL CELL RESEARCH.  312:3370-3378.

Precancerous stem cells have the potential for both benign and malignant differentiation.  FASEB JOURNAL.  20:a1326-a1327.

P-128 Establishment and characterization of a line of transgenic miceharboring a lung specific human type II p53(175H) mutation; a potential model of human disease

Phase II randomized study of mitomycin C (MMC) as a modulator of irinotecan in patients (pts) with esophageal and GE junction adenocarcinomas.  JOURNAL OF CLINICAL ONCOLOGY.  23:4027-4027.

Expression of Pirh2, a newly identified ubiquitin protein ligase, in lung cancer.  JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE.  96:1718-1721.

5-aza-2 '-deoxycytidine activates the p53/p21(Waf1/Cip1) pathway to inhibit cell proliferation

p21 response to DNA damage induced by genistein and etoposide in human lung cancer cells.  BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS.  305:950-956.

Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21^Cip1 promoter.  MOLECULAR AND CELLULAR BIOLOGY.  23:4056-4065.

Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.  ONCOGENE.  21:7831-7838.

RT-PCR heteroduplex analysis permits differentiation of transgene and host gene expression in a transgenic animal model.  BIOTECHNIQUES.  33:58-+.

Increased expression of unmethylated CDKN2D by 5-aza-2 '-deoxycytidine in human lung cancer cells.  ONCOGENE.  20:7787-7796.

Extra-pair paternity in waved albatrosses.  MOLECULAR ECOLOGY.  9:1415-1419.

Evolution of the ribosomal RNA internal transcribed spacer one (ITS-1) in cichlid fishes of the Lake Victoria region.  MOLECULAR PHYLOGENETICS AND EVOLUTION.  11:273-282.

Breeding behavior of isolation-reared sandhill cranes.  JOURNAL OF FIELD ORNITHOLOGY.  68:200-207.

Isolation of a sex-linked DNA sequence in cranes.  JOURNAL OF HEREDITY.  92:392-397.

Targeting mutant p53 protein in spontaneous non-small cell lung cancers in transgenic mice..  CANCER RESEARCH.

Deregulation of mTOR signaling contributes to chemoradiation resistance in lung squamous cell carcinoma.  CANCER RESEARCH.

Mutant TP53 action in lung dictated by the cell microenvironment.  CANCER RESEARCH.

Pan-cancer Feature Selection and Classification Reveals Important Long Non-coding RNAs.  2417-2424.

Abstract 2568: Investigation of Fanconi Anemia pathway downstream genes.  CANCER RESEARCH. 2568-2568.

Abstract 3546: miRNA expression of spontaneous non-small cell lung cancers in p53 mutant transgenic mice following exposure to PRIMA-1.  CANCER RESEARCH. 3546-3546.

Abstract 3548: Differential miRNA expression levels and risk of lung adenocarcinoma in transgenic mice.  CANCER RESEARCH. 3548-3548.

Differential miRNA expression levels and risk of lung adenocarcinoma in transgenic mice.  CANCER RESEARCH.

Investigation of Fanconi Anemia pathway downstream genes.  CANCER RESEARCH.

miRNA expression of spontaneous non-small cell lung cancers in p53 mutant transgenic mice following exposure to PRIMA-1.  CANCER RESEARCH.

Assessment of the Fanconi anemia repair pathway as a predictor of clinical activity of pembrolizumab (PEM)..  JOURNAL OF CLINICAL ONCOLOGY.

Phase II trial of pembrolizumab in patients with solid tumors functionally competent or deficient for the Fanconi Anemia repair pathway.  EUROPEAN JOURNAL OF CANCER. E26-E26.

Micro RNA-200C is one of the important Fanconi Anemia (FA) pathway downstream regulators in lung cancer.  CANCER RESEARCH.

Evaluating immune checkpoint inhibition in solid tumor patients with homologous recombination repair deficiency..  JOURNAL OF CLINICAL ONCOLOGY.

Abstract 4442: micoRNA in FA defective tumor.  CANCER RESEARCH. 4442-4442.

Abstract 4438: Promoter hypermethylation status of Fanconi Anemia (FA) pathway genes FANCF, FANCL and FANCS in non-small cell lung cancer (NSCLC).  CANCER RESEARCH. 4438-4438.

Abstract 3866: Potential oncogenic function of Rad51C splice variant in colorectal tumors.  3866-3866.

Inhibition of pro-survival pathways in lung cancer cells with functional defects in the Fanconi Anemia pathway.  CANCER RESEARCH.

Abstract 2407: Investigation of Novel Rad51c-ATXN7 fusion gene in colorectal tumors.  2407-2407.

Abstract 5434: Combined BCL-2/XL and mTor inhibition promotes apoptosis in small cell lung cancer.  5434-5434.

Abstract 4221: Mutations in Rad51C in colon tumors..  CANCER RESEARCH. 4221-4221.

Abstract 4246: Promoter hypermethylation and gene expression of FANCF in non-small cell lung cancer (NSCLC)..  CANCER RESEARCH. 4246-4246.

Abstract 4365: Sensitivity of small cell lung cancer cells with defective Fanconi Anemia (FA) pathway to BCL2 inhibitors...  CANCER RESEARCH. 4365-4365.

Abstract 4439: Targeting FANCD2 as a radiosensitizer in pediatric rhabdomyosarcoma..  CANCER RESEARCH. 4439-4439.

Abstract LB-139: Phase I trial of veliparib or mitomycin (MMC) + veliparib in patients with sporadic solid tumors screened for somatic deficiency in the Fanconi Anemia (FA) pathway..  CANCER RESEARCH. lb-139-lb-139.

Abstract 4082: Global miRNA expression changes induced by HDAC-42 and 5-azaCdr in lung cancer cells.  CANCER RESEARCH. 4082-4082.

Abstract 4682: Compensatory activation of alternative DNA repair pathways following exposure to the PARP Inhibitor ABT-888 in vitro and in patients with solid malignancies.  CANCER RESEARCH. 4682-4682.

Abstract 4740: Establishment of P53 mutant type specific spontaneous lung tumor in transgenic mice for treatment.  CANCER RESEARCH. 4740-4740.

Abstract A99: Phase I trial of veliparib or mitomycin C + veliparib in pts with Fanconi anemia pathway (FA) repair defects..  MOLECULAR CANCER THERAPEUTICS. a99-a99.

Abstract 5500: Inhibition of poly(ADP-ribose) polymerase in lung cancer cells with defective Fanconi anemia (FA) pathway.  CANCER RESEARCH. 5500-5500.

Abstract 610: Regression of spontaneous non-small cell lung cancers in P53 mutant transgenic mice following exposure to PRIMA-1.  CANCER RESEARCH. 610-610.

Abstract 3750: Functional analysis of the Fanconi Anemia pathway in primary lung tumors.  CANCER RESEARCH. 3750-3750.

Fanconi anemia repair pathway as a predictor of anti-tumor activity of pembrolizumab: interim analysis of open-label, single-arm phase II trial.  GYNECOLOGIC ONCOLOGY. S66-S67.

Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway..  JOURNAL OF CLINICAL ONCOLOGY.

The Oncogenic Potential of a Mutant TP53 Gene Explored in Two Spontaneous Lung Cancer Mice Models

The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models

The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models

Utilizing novel fluorothymidine PET imaging in a phase I study of veliparib on an intermittent and continuous schedule given in combination with carboplatin in metastatic breast cancer